When to use Signatera™ MRD test?
Neoadjuvant Setting
- To assess response to neoadjuvant therapy to help inform next steps
Adjuvant Setting
- Use after surgery to evaluate the need for adjuvant chemotherapy and inform when to escalate or right-size treatment
Surveillance Setting
- Detect MRD with greater sensitivity than current standard of care tools
- Signatera™ is meant to be used serially to detect relapse earlier
“Detecting relapse before it becomes clinically symptomatic requires a test with high sensitivity and specificity. Signatera™ enables us to confidently identify patients with molecular relapse when the disease burden is so low that it is undetectable with imaging.”
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Not all MRD assays are created equal
Considerations when choosing patient monitoring tools:
Comprehensive clinical validation
Demonstrated real-world experience
Personalized and tumor-informed
Extensively validated
Signatera™ has been validated in >65 peer-reviewed publications studying >6,500 patients across >25 tumor types1-6
Deep experience
Signatera™ has been used to manage over 200,000 patients and has been ordered by more than 1/3 of US oncologists6
Covered by Medicare for multiple solid tumor indications
Stage II-IV and oligometastatic colorectal cancer (CRC) in the adjuvant and recurrence monitoring settings
Stage II-IV breast cancer in the neoadjuvant setting, regardless of subtype
Stage IIb and higher breast cancer in the adjuvant and recurrence monitoring settings
Muscle invasive bladder cancer (MIBC) in the adjuvant and recurrence monitoring settings
Stage II-IV ovarian, fallopian tube, or primary peritoneal cancer in the adjuvant and recurrence monitoring settings
For monitoring of response to immune-checkpoint inhibitor (ICI) therapy for patients with any solid tumor
Is Signatera™ right for your patients?
We’re here to help you find out
References
1Reinert T, Henriksen TV, Christensen E, et al. JAMA Oncol. 2019. doi:10.1001/jamaoncol.2019.0528.
2Coombes RC, et al., Clin Cancer Res, 2019.
3Lebow, et al., Front. Oncol, 2023.
4Christensen E, et al. J Clin Oncol, 2019.
5Kotani D. et al, Nature Medicine, 2023.
6Data on file